Capital Advisors Ltd. LLC Has $104,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Capital Advisors Ltd. LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.9% during the first quarter, Holdings Channel reports. The fund owned 1,420 shares of the biopharmaceutical company’s stock after acquiring an additional 162 shares during the quarter. Capital Advisors Ltd. LLC’s holdings in Gilead Sciences were worth $104,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Schonfeld Strategic Advisors LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth about $896,000. Truist Financial Corp grew its position in shares of Gilead Sciences by 1.4% in the third quarter. Truist Financial Corp now owns 573,445 shares of the biopharmaceutical company’s stock valued at $42,974,000 after purchasing an additional 7,890 shares during the last quarter. Axxcess Wealth Management LLC grew its position in shares of Gilead Sciences by 61.5% in the third quarter. Axxcess Wealth Management LLC now owns 14,899 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 5,674 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Gilead Sciences by 7.3% during the third quarter. Ameriprise Financial Inc. now owns 1,703,783 shares of the biopharmaceutical company’s stock worth $127,675,000 after purchasing an additional 115,189 shares during the period. Finally, Alps Advisors Inc. lifted its holdings in Gilead Sciences by 3.2% during the 3rd quarter. Alps Advisors Inc. now owns 348,691 shares of the biopharmaceutical company’s stock worth $26,131,000 after purchasing an additional 10,670 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $68.40 on Wednesday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The company has a market cap of $85.22 billion, a price-to-earnings ratio of 190.00, a PEG ratio of 2.92 and a beta of 0.18. The firm has a 50 day simple moving average of $66.01 and a 200 day simple moving average of $72.42.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.37 EPS. Research analysts predict that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.50%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a research report on Wednesday, April 24th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Oppenheimer restated an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. UBS Group lowered their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, Barclays cut their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. Twelve investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Hold” and an average price target of $83.47.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.29% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.